NVG-291 is under clinical development by NervGen Pharma and currently in Phase II for Spinal Cord Injury. According to GlobalData, Phase II drugs for Spinal Cord Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NVG-291 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NVG-291 overview
NVG-291 is under development for the treatment of spinal cord injury, relapsing remitting multiple sclerosis, multiple sclerosis, Alzheimer's disease, traumatic brain injury and stroke .The therapeutic candidate is an intracellular sigma peptide (ISP) mimetic of PTP sigma wedge domain conjugated to TAT, a trans-activator of transcription and administered through subcutaneous route. It acts by targeting receptor-type tyrosine-protein phosphatase sigma. The drug candidate is developed based on nerve regeneration technology.
It was also under development for the treatment of amyotrophic lateral sclerosis.
NervGen Pharma overview
NervGen Pharma (NervGen) is a regenerative medicine company that strives to develop innovative therapies for the treatment of nerve damage such as paralysis and neurodegenerative diseases. The company’s technology aims at the protein tyrosine phosphatase sigma (PTPs), a critical neural receptor which suppresses nerve regeneration in patients suffering from spinal cord injury and other medical conditions. Blocking the PTPs receptor was shown to promote regeneration of damaged nerves and improvement of nerve function. NervGen intends to harness its technology to identity, evaluate and develop new drug candidates for other medical conditions such as stroke, peripheral nerve injury, multiple sclerosis and heart attack. The company has collaboration with Case Western Reserve University. NervGen is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of NVG-291’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
